首页> 外文OA文献 >Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)

【2h】

Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)

机译：Medicare患者的90天休息和长期死亡率（≥65岁）用皮千种冠状动脉干预后用TicagreloR与普拉布雷治疗（来自密歇根心血管联盟的蓝色交叉蓝盾）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chris Song; Devraj Sukul; Milan Seth; James M. Dupree; Akshay Khandelwal; Simon R. Dixon; David Wohns; Thomas LaLonde; Hitinder S. Gurm;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (= 65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium) [J] . Song Chris, Sukul Devraj, Seth Milan, The American Journal of Cardiology . 2017,第11期

机译：Medicare患者的90天升级和长期死亡率（＆ = 65岁）用冠状动脉介入后用TicagreloR与普拉布雷治疗（来自密歇根心血管联盟的蓝色交叉蓝盾）
2. TCT-81 The Comparative Effectiveness and Safety of Impella Versus Intra-Aortic Balloon Pump in Patients who Underwent Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) [J] . Devraj Sukul, Milan Seth, Akshay Khandelwal, Journal of the American College of Cardiology . 2018,第13期

机译：TCT-81患有经皮冠状动脉介入的患者的VALBLALLA对主动脉泵的比较有效性和安全性：密歇根州心血管联盟的蓝色交叉蓝盾的见解（BMC2）
3. TCT-81 The Comparative Effectiveness and Safety of Impella Versus Intra-Aortic Balloon Pump in Patients who Underwent Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) [J] . Devraj Sukul, Milan Seth, Akshay Khandelwal, Journal of the American College of Cardiology . 2018,第13期

机译：TCT-81患有经皮冠状动脉介入的患者的VALBLALLA对主动脉泵的比较有效性和安全性：密歇根州心血管联盟的蓝色交叉蓝盾的见解（BMC2）
4. Contemporary Trends and Outcomes Associated with the Pre-Procedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) [O] . Devraj Sukul, Milan Seth, Simon R. Dixon, -1

机译：在接受经皮冠状动脉介入治疗的患者中术前使用口服P2Y12抑制剂的相关趋势和结果：密歇根州心血管协会（BMC2）的蓝十字蓝盾的见解
5. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium [O] . Devraj Sukul, Milan Seth, Theodore Schreiber, 2017

机译：Bivalirudin对肝素单疗法对透析患者进行经皮冠状动脉介入的比较安全性和有效性：密歇根州心血管联盟的蓝色横向蓝盾的见解
6. Blue Cross Blue Shield Association Did Not Claim Some Allowable Medicare Postretirement Benefit Costs For Fiscal Years 2002 Through 2010 [R] . 2014

机译：2002年到2010年，蓝十字蓝盾协会没有申请一些允许的医疗保险后退休补助费用

Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)

著录项

引文网络

相似文献

相关主题

期刊订阅